Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: An open-label, single-dose study

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 6, 2004, Pages 514-524

  Mross, Klaus ^a   Niemann, Bernward ^a   Massing, Ulrich ^a   Drevs, Joachim ^a   Unger, Clemens ^a   Bhamra, Rupinder ^b   Swenson, Christine E ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Liposome Company Incorporated   (United States)

Author keywords

Liposomal doxorubicin; Pharmacokinetics; Safety; Tolerability

Indexed keywords

DOXORUBICIN; DOXORUBICINOL; LIPOSOME;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULARY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; HUMAN; MICROENCAPSULATION; NAUSEA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE CANCER; SOLID TUMOR; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HALF-LIFE; HEART; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; TISSUE DISTRIBUTION; VOMITING;

EID: 11144336676     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0825-y     Document Type: Article

References (26)

1. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905
2. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, Boxenbaum H, Welles L, Chow S-C, Bhamra R, Chasikin P (2003) Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 14:239-246
3. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454
4. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36
5. Chabner BA, Allegra CJ, Curt GA, Calabresi P (1996) Antineoplastic agents. In: Hardman JG, Limbird LE (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York, pp 1264-1266
6. Takanashi S, Bachur N (1976) Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos 4:79-87
7. Mross K, Maessen P, van der Vijgh WJF, Gall H, Boven E, Pinedo HM (1988) Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517-526
8. Speth PAJ, Van Hoesel QGCM, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15-31
9. Loo TL, Freireich EJ (1995) Cancer chemotherapeutic drugs. In: PL Munson (ed) Principles of pharmacology: basic concepts and clinical application. Chapman & Hall, New York, pp 1475-1516
10. Robert J (1998) Anthracyclines. In: Grochow LB, Ames MM (eds) A clinician's guide to chemotherapy: pharmacokinetics and pharmacodynamics. William and Wilkins, Philadelphia
11. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker
12. Chan KKH, Gibaldi M (1982) Estimation of statistical moments and steady-state volume of distribution for a drug given by intravenous infusion. J Pharmacokinet Biopharm 10:551-558
13. Robert J, Gianni L (1993) Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17:219-252
14. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 21:221-228
15. Jacquet J-M, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, Rossi JF (1990) Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27:219-225
16. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53:555-561
17. Amantea MA, Forrest A, Northfeldt DW, Mamelok R (1997) Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61:301-311
18. Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, et al (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 13:910-918
19. Keller AM, Mennel RG, Nabholtz JM, Georgoulias V, Emanuel DJ, Tendler CL (2001) Phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, abstract 115
20. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037-1047
21. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136:1475-1480
22. Hong RL, Tseng YL (2001) Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 91:1826-1833
23. Mross K (1993) Klinische und pharmakologische Untersuchungen zur Pharmakokinetik, Metabolisierung, Pharmakodynamik und Toxizität von Anthrazyklinen W. Zuckschwerdt Verlag München, Aktuelle Onkologie 76
24. Massing U, Fuxius S (2000) Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat 3:171-177
25. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang F, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992
26. Mross K, Gierlich T, Häring B, März W, Unger C (2002) Clinical and pharmacokinetics study with liposomal doxorubicin (DL-1) in patients with advanced metastatic cancer - results from a phase-I study. Int J Clin Pharmacol Ther 40:387-388